Ecallantide (trade name Kalbitor investigational name DX-88) is a drug used for the treatment of hereditary angioedema (HAE) and in the prevention of blood loss in cardiothoracic surgery. It is an inhibitor of the protein kallikrein and a 60-amino acid polypeptide which was developed from a Kunitz domain through phage display to mimic antibodies inhibiting kallikrein. On November 27 2009 ecallantide was approved by the U.S.
ATC prefix
B06
ATC suffix
AC03
CAS number
460738-38-9
FDA UNII code
5Q6TZN2HNM
IUPAC name
[Glu20Ala21Arg36Ala38His39Pro40Trp42]tissue factor pathway inhibitor (human)-(20-79)-peptide (modified on reactive bond region Kunitz inhibitor 1 domain containing fragment)
This page contains content from the copyrighted Wikipedia article "Ecallantide"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.